Oxford Nanopore Technologies plc (LSE:ONT) shares fell 0.65% to 213.6p in the latest session, placing the DNA and RNA sequencing company among the notable decliners on the London market. The move follows half-year results that showed higher revenue, a much improved gross margin and a sharply narrower loss, alongside weakness in parts of Asia.

The central question for investors is how quickly the company can convert growth and cost control into adjusted EBITDA breakeven, which management now targets for FY27.

Key Highlights

For the six months to 30 June 2026, Oxford Nanopore reported revenue of £116.7 million, up 11% (12% at constant currency) from £105.6 million.

Gross profit rose 18% to £72.6 million, lifting the gross margin to 62.2% from 58.2%.

The adjusted EBITDA loss narrowed to £22.1 million from £48.3 million, while the pre-tax loss narrowed to £44.9 million from £69.0 million. Adjusted operating costs fell 6.9% year on year.

Management raised its cost guidance for FY2026 and said it is tracking towards adjusted EBITDA breakeven in FY27, with positive free cash flow projected for 2028.

About Oxford Nanopore Technologies plc

Oxford Nanopore Technologies plc (LSE:ONT) develops and sells nanopore-based sequencing technology that analyses DNA and RNA. Its devices can read long fragments of genetic material and deliver results in real time, from portable instruments through to high-throughput systems.

Customers span research institutions, biopharma companies, clinical laboratories and industrial users. The group generates revenue mainly from consumables used on its devices, which makes usage and the installed base of instruments important drivers.

The company has set a revenue target of above USD700 million by 2030, which places the current focus on scaling clinical and biopharma applications while bringing operating costs under control.

Why Is LSE:ONT Down Today?

The 0.65% decline to 213.6p comes against a mixed fundamental backdrop. Operating progress in the half was clear, but investors still weigh a loss-making business against a path to profitability that depends on execution.

Regional performance was uneven. Europe, the Middle East, Africa and India grew 24% at constant currency and the Americas 13%, while Asia Pacific fell 8.4%, including a 16% fall in China.

By end market, clinical grew 35% and biopharma 25%, while industrial rose 6.2% and research 5.4%. The mix shows demand moving towards applied uses, though research funding remains an important part of the customer base.

Key Reasons Behind the Downtick

The first factor is China. A 16% decline in the country weighed on Asia Pacific and shows how sensitive the group is to regional demand and trade conditions.

The second factor is continued losses. Even after the improvement, the company reported an adjusted EBITDA loss of £22.1 million and a pre-tax loss of £44.9 million.

Third, research demand grew only 5.4%. Academic and government budgets can be uneven, so reliance on this segment can limit growth in some periods.

Another consideration is guidance expectations. FY2026 constant-currency revenue growth of 16% to 20% implies a faster second half than the 12% achieved in H1, and investors will monitor delivery closely.

Finally, the company's Middle East exposure is not reported separately, which leaves some uncertainty about the regional effect of geopolitical disruption.

Key Growth Catalysts

The most important catalyst is clinical adoption. Growth of 35% in clinical shows increasing use of nanopore sequencing in healthcare-related testing and research.

BioPharma is another driver, growing 25%. Pharmaceutical customers use sequencing across discovery, development and quality workflows.

Margin improvement is a third catalyst. The gross margin rose to 62.2%, and FY2026 guidance is for a gross margin of around 62%.

Cost discipline also matters. Adjusted operating costs are now expected to be flat to down 2% in FY2026, compared with previous guidance of 0% to 5% growth.

Finally, CEO Francis Van Parys said the company is "tracking well towards adjusted EBITDA breakeven in FY27," and the 2030 revenue target of above USD700 million provides a longer-term framework.

Risks

The most significant risk for LSE:ONT is a delay in reaching breakeven. If revenue growth slows or costs rise, the path to profitability could extend.

Regional risk is another factor. China weakness and wider geopolitical issues can affect demand and supply chains.

Competition is also important. Sequencing is a technology-intensive field with established and emerging rivals, and customers can switch platforms.

Reliance on research funding is relevant, since public and academic budgets can change.

Finally, adoption in clinical markets can depend on regulation, reimbursement and validation requirements, which can take time.

Valuation

The valuation of LSE:ONT is likely to be viewed through revenue growth, margin progress and the timing of breakeven rather than through current earnings.

At 213.6p, investors are weighing a business with improving gross margin, falling operating costs and a clear breakeven target against ongoing losses and regional uncertainty.

Reference points include FY2026 revenue growth guidance of 16% to 20% at constant currency, a gross margin of around 62% and the 2030 revenue target of above USD700 million.

The central valuation debate is whether the company can deliver growth and cost savings together while sustaining its technological position.

What Investors Should Watch Next

The next key event is the full-year results, which should show whether revenue, gross margin and cost guidance were met.

Investors should follow clinical and biopharma growth, consumables usage, China trends and the pace of operating cost reduction.

Other points to monitor include progress towards FY27 adjusted EBITDA breakeven, cash resources and any update to the 2030 targets.

For LSE:ONT, the central question over the coming quarters is whether growth in clinical and biopharma markets can offset weaker regions while the loss continues to narrow.